

Raltegravir (RAL) Interactions (also see drug package inserts)

Class or Drug	Mechanism of Action	Clinical Comments
Antacids and other polyvalent cations [Kiser, et al. 2010; Calcagno, et al. 2015; Krishna, et al. 2016]	RAL chelates with cations, forming insoluble compounds that inactivate both drugs.	<ul style="list-style-type: none"> • Administer RAL 2 hours before or 6 hours after taking antacids. • CaCO₃ antacids are contraindicated with RAL HD (2 x 600 mg tablets). • CaCO₃ antacids can be taken with twice-daily RAL (400 mg) with no dose adjustments.
Anticonvulsants	Coadministration with strong inducers of UGT1A1 (phenytoin, phenobarbital, etc.) may decrease RAL concentrations.	Coadministration with strong inducers of UGT1A1 are not recommended.

Abbreviation: UGT1A1, uridine diphosphate glucuronosyltransferase 1A1.

No significant interactions/no dose adjustments necessary: Common oral antibiotics; drugs used as antihypertensive agents; anticoagulants; antiplatelet drugs; statins; antidiabetic drugs; acid-reducing agents; asthma and allergy medications; long-acting beta agonists; inhaled and injected corticosteroids; antidepressants; benzodiazepines; sleep medications; antipsychotics; non-opioid pain medications; opioid analgesics and tramadol; hormonal contraceptives; erectile and sexual dysfunction agents; tobacco and smoking cessation products; alcohol, disulfiram, and acamprosate; methadone, buprenorphine, naloxone, and naltrexone; immunosuppressants.

References

- Calcagno A, D'Avolio A, Bonora S. Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients. *Expert Opin Drug Metab Toxicol* 2015;11(7):1167-1176. [PMID: 26073580] <https://www.ncbi.nlm.nih.gov/pubmed/26073580>
- Kiser JJ, Bumpass JB, Meditz AL, et al. Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers. *Antimicrob Agents Chemother* 2010;54(12):4999-5003. [PMID: 20921313] <https://www.ncbi.nlm.nih.gov/pubmed/20921313>
- Krishna R, East L, Larson P, et al. Effect of metal-cation antacids on the pharmacokinetics of 1200 mg raltegravir. *J Pharm Pharmacol* 2016;68(11):1359-1365. [PMID: 27671833] <https://www.ncbi.nlm.nih.gov/pubmed/27671833>